Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Pathways (CLPA) -- Ignore unavailable to you. Want to Upgrade?

To: Epicenter who wrote (61)	12/13/1998 7:42:00 PM
From: bob	Read Replies (1) \| Respond to of 566

Epicenter, I believe Dr. Pamukcu stated that they have not seen any toxic effects on tissue other than the neoplastic type. A quote from the latest release hints at this: "''Exisulind acts via a mechanism we began to uncover several years ago. This mechanism involves a previously undescribed phosphodiesterase (PDE) that specifically degrades cyclic GMP (cGMP), similar to members of the PDE5 gene family. This new PDE, which is the subject of additional pending patent applications, is involved in regulating apoptosis in neoplastic (precancerous and cancerous) cells,'' said Rifat Pamukcu, M.D., chief scientific officer at Cell Pathways. Further on, Dr. Joe Thompson states: "Dr. Thompson added, ''Targeting the new cGMP-PDE, our research group has discovered compounds that have up to 20,000 times the apoptotic potency of exisulind. Like exisulind, these new compounds affect neoplastic cells without inducing apoptosis in normal cells in cell culture." Frankly, things look promising IMO. So far I can't see anything wrong here. Publication in a peer reviewed journal will help clear this up. Don't know what tomorrow will bring, CNBC could be very positive or could be negative due to the small initial patient population for APC and Prevatac. We'll see... Bob